RMRobert M. Minutello

Robert M. Minutello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert M. Minutello has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Shing Chiu Wong

    Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA

    10 shared publications
  • Geoffrey Bergman

    Department of Medicine, Division of Cardiology, Weill Cornell Medicine – New York Presbyterian Hospital, Weill Cornell Cardiovascular Outcomes Research Group (CORG) and the Greenberg Institute for Cardiac Electrophysiology, NY (E.V.R., C.F.L., S.C.W., G.B., J.E.I., G.T., S.M.M., B.B.L., L.K.K., J.W.C.).

    8 shared publications
  • Dmitriy N. Feldman

    Division of Cardiology, Department of Medicine, Weill Cornell Medicine New York‐Presbyterian Hospital New York NY

    7 shared publications
  • Luke K. Kim

    Weill Cornell Cardiovascular Outcomes Research Group (CORG), Weill Cornell Medical College, New York, NY 10021, USA

    7 shared publications
  • Harsimran Sachdeva Singh

    Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, USA

    5 shared publications
  • Ilhwan Yeo

    Department of Medicine, Division of Cardiology, Weill Cornell Medicine—New York Presbyterian Hospital and Weill Cornell Cardiovascular Outcomes Research Group (CORG) , 520 East 70th Street 4th Floor, New York, NY 10021

    4 shared publications

Latest Publications

  • Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions

    by Daniel Y. Lu, Jaya Kanduri, Ilhwan Yeo, Parag Goyal, Udhay Krishnan, Evelyn M. Horn, Maria G. Karas, Irina Sobol, David T. Majure, Yoshifumi Naka, et al.

    BACKGROUND: Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes. METHODS: HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, and mechanical ventilation). Multivariable logistic regression was performed to adjust for the presence of HF decompensations and significant clinical variables during univariate analysis. RESULTS: A total of 2 331 690 hospitalizations (81.2%) were admissions to non-ATCs (94.5% of centers), 525 037 (18.3%) were admissions to ATCs (5.5% of centers), and 15 541 (0.5%) were transferred to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths of stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, P P P P P P <0.001) patients, with similarly lower multivariable-adjusted mortality. CONCLUSIONS: Patients with HF treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality.


  • Open Access

    Impella Versus Intra‐Aortic Balloon Pump in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: An Observational Study

    by Ilhwan Yeo, Rachel Axman, Daniel Y. Lu, Dmitriy N. Feldman, Jim W. Cheung, Robert M. Minutello, Maria G. Karas, Erin M. Iannacone, Ankur Srivastava, Natalia I. Girardi, et al.

    Background: Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) is increasingly used for patients with cardiogenic shock. Although Impella or intra‐aortic balloon pump (IABP) is frequently used for left ventricular unloading (LVU) during VA‐ECMO treatment, there are limited data on comparative outcomes. We compared outcomes of Impella and IABP for LVU during VA‐ECMO. Methods and Results: Using the Nationwide Readmissions Database between 2016 and 2020, we analyzed outcomes in 3 groups of patients with cardiogenic shock requiring VA‐ECMO based on LVU strategies: extracorporeal membrane oxygenation (ECMO) only, ECMO with IABP, and ECMO with Impella. Of 15 980 patients on VA‐ECMO, IABP and Impella were used in 19.4% and 16.4%, respectively. The proportion of patients receiving Impella significantly increased from 2016 to 2020 (6.5% versus 25.8%; P ‐trendP =0.02). ECMO with Impella versus ECMO only had similar in‐hospital mortality (aOR, 1.09; P =0.695) but was associated with more bleeding (aOR, 1.21; P =0.007) and more acute kidney injury requiring hemodialysis (aOR, 1.42; P P =0.002), higher in‐hospital mortality (aOR, 1.32; P =0.001), and higher 40‐day mortality (hazard ratio, 1.25; P <0.001). Conclusions: In patients with cardiogenic shock on VA‐ECMO, LVU with Impella, particularly with 2.5/CP, was not associated with improved survival at 40 days but was associated with increased adverse events compared with IABP. More data are needed to assess Impella platform‐specific comparative outcomes of LVU.


  • Open Access

    Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions

    by Daniel Y Lu, Jaya Kanduri, Ilhwan Yeo, Parag Goyal, Udhay Krishnan, Evelyn M Horn, Maria G Karas, Irina Sobol, David T Majure, Yoshifumi Naka, et al.

    Background Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data is lacking on decompensated heart failure (HF) admissions and transfers, and the impact of advanced therapy centers (ATCs) on outcomes. Methods HF hospitalizations were obtained from the Nationwide Readmissions Database 2016-2019. Centers performing at least one heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among three cohorts: admissions to non-ATCs, admissions to ATCs, transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, mechanical ventilation). Results 2,331,690 hospitalizations were admissions to non-ATCs (94.5% of centers), 525,037 were admissions to ATCs (5.5% of centers), and 15,541 were transfers to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, pConclusions HF patients treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality. Clinical Perspective Contemporary data is lacking on admissions and transfers for decompensated heart failure (HF) and the impact of advanced therapy centers (ATCs) on outcomes. Our findings show that decompensated HF patients treated at ATCs had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. While unadjusted mortality was higher at ATCs, multivariable adjusted mortality was significantly lower at ATCs, both for directly admitted and transferred patients. Our findings will hopefully prompt earlier recognition and referral of patients to ATCs, emphasize the need for increased numbers of ATCs, and spark further research into the decision-making process for referral to ATCs.

  • Open Access

    Feasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis

    by Ilhwan Yeo, Shing-Chiu Wong, Charles A. Mack, Willis Ko, Luke K. Kim, Dmitriy N. Feldman, Mark Reisman, Stephanie L. Mick, Erin M. Iannacone, Tara Shah, et al.


  • TCT-425 Perclose or Manta Post-TAVR (PROMPT) Study

    by S. Chiu Wong, Robert Minutello, Geoffrey Bergman, Stephanie Mick, Erin Iannacone, Dmitriy Feldman, Luke Kim, Harsimran Singh, Mark Reisman

  • Open Access

    Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis

    by Sun-Joo Jang, Ilhwan Yeo, Chanel Jonas, Parag Goyal, Jim W. Cheung, Dmitriy N. Feldman, S. Andrew McCullough, Udhay Krishnan, David L. Narotsky, Harsimran S. Singh, et al.

    The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.


  • Functional Mitral Regurgitation in Heart Failure

    by Tara Shah, Ming Zhong, Robert M. Minutello

    Functional mitral regurgitation (FMR) in the setting of left ventricular (LV) dysfunction and heart failure portends a poor prognosis. Guideline-directed medical therapy remains the cornerstone of initial treatment, with emphasis placed on treatment of the underlying LV dysfunction, as FMR is a secondary phenomenon and a disease due to LV remodeling. Surgical correction of FMR is controversial because it typically does not address the underlying mechanism and etiology of the condition. However, new, minimally invasive transcatheter therapies, in particular the MitraClip system, have shown promise in the treatment of FMR in selected patients. This review will summarize the pathophysiology underlying FMR, the prognosis of patients with heart failure and FMR, and the various medical and procedural treatment options currently available and under investigation.


  • The Influence of Gender on In-Hospital Clinical Outcome Following Isolated Mitral or Aortic Heart Valve Surgery

    by S. Chiu Wong, Ilhwan Yeo, Geoffrey Bergman, Dmitriy N. Feldman, Harsimran Singh, Robert Minutello, Luke K. Kim


  • Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction

    by Udhay Krishnan, Josef A. Brejt, Joshua Schulman-Marcus, Rajesh V. Swaminathan, Dmitriy N. Feldman, Parag Goyal, S. Chiu Wong, Robert M. Minutello, Geoffrey Bergman, Harsimran Singh, et al.


  • Analysis of reperfusion time trends in patients with ST-elevation myocardial infarction across New York State from 2004 to 2012

    by Subhi J. Al'ARef, S. Chiu Wong, Rajesh V. Swaminathan, Patrick McNair, Dmitriy N. Feldman, Luke K. Kim, Harsimran S. Singh, Geoffrey Bergman, Robert M. Minutello